DR CAROL WORTH – CHIEF TECHNICAL MANAGER
Dr. Worth has been working in the area of drug delivery systems for over 25 years at various international companies. As a development chemist, she liaised between companies in USA, UK and Asia to develop oral formulations of injectable peptide hormones. She has since been involved in the development of novel anticancer drugs and, most recently, topical pain relief formulations. Dr Worth has extensive experience in the setting up and running of GMP accredited laboratories and development of robust products suitable for GMP manufacturing. Dr. Worth has a PhD in Natural Product Chemistry from the University of Western Australia.
ANDREW CURTIS – VICE PRESIDENT, BUSINESS DEVELOPMENT & ALLIANCE MANAGEMENT (BASED IN THE USA)
Andrew leads the Company’s US and European business development efforts, including the out-licensing of SUDA’s portfolio of programs, the development of industry partnerships, and leading the presence SUDA’s US-based commercial efforts. Andrew has held senior management roles at Genzyme-Sanofi, Merck, J&J, and Pfizer, in a range of commercial functions, including Corporate Strategy, Business Development, Commercial Development, and Sales and Marketing. He has also worked in the biotech sector for two German companies, Jerini and Affimed. Additionally, Andrew founded Rising Tide Therapeutics, a novel biotech entity focused on finding a cure for alpha antitrypsin deficiency, a rare genetic pulmonary disease. Andrew has broad therapeutic experience in Rare Diseases, Oncology, CNS, Pain, Wound Healing, Biosimilars, and Metabolic Bone Disease.
DR DEBORAH COOPER – PROJECT MANAGER
Dr Deborah Cooper is a Biotech professional with 25 years’ experience, expert in Cell Biology/Immunology, Clinical, Manufacturing, Product Development and Project Management. Deborah has 12 years in management of commercial technology organisations, including 7 years at the executive level. Deborah has worked for 4 years as an independent consultant to the Biotech sector, involved in managing product development, commercialisation strategy, regulatory submissions, grant applications, feasibility studies, GMP facilities, intellectual property management and placement of contract manufacturing, pre-clinical and clinical studies. Deborah has worked for 9 years in scientific research in private, not for profit and academic organisations; and 7 years studying at recognised tertiary institutions, achieving qualifications to the PhD level in the biological sciences arena.
JOSEPH OHAYON – CHIEF FINANCIAL OFFICER & COMPANY SECRETARY
Joseph Ohayon joined the company in July 2010 as the Chief Financial Officer and in March 2011 he took over the role of Company Secretary. He has over 30 years experience in financial roles including 18 years within health-related industries. Joseph qualified as a Chartered Accountant in the UK and graduated with a Masters of Business Administration in International Business from Murdoch University in 2007.